Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT

Jakob R Passweg; Helen Baldomero; Tobias Alexander; Emanuele Angelucci; Dina Averbuch; Ali Bazarbachi; Fabio Ciceri; Greco Raffaella; Mette D Hazenberg; Krzysztof Kalwak; Donal P McLornan; Antonio M Risitano; Annalisa Ruggeri; John A Snowden; Anna Sureda

doi:10.1038/s41409-024-02459-0

Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT

Bone Marrow Transplant. 2024 Nov 22. doi: 10.1038/s41409-024-02459-0. Online ahead of print.

Authors

Affiliations

¹ Hematology Division, EBMT Activity Survey Office, University Hospital, Basel, Switzerland.
² Hematology Division, EBMT Activity Survey Office, University Hospital, Basel, Switzerland. [email protected].
³ Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
⁴ Hematology and Cellular Therapy Unit. IRCCS Ospedale Policlinico San Martino, Genova, Italy.
⁵ Faculty of Medicine, Hebrew University of Jerusalem; Hadassah Medical Center, Jerusalem, Israel.
⁶ Department of Internal Medicine, Bone Marrow Transplantation Program, American University of Beirut, Beirut, Lebanon.
⁷ Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.
⁸ Department of Hematology, Amsterdam University Medical Centres, University of Amsterdam, and Department of Hematopoiesis, Sanquin Research, Amsterdam, The Netherlands.
⁹ Clinical Department of Pediatric BMT, Hematology and Oncology, Wroclaw Medical University, Wroclaw, Poland.
¹⁰ Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
¹¹ Hematology and Hematopoietic Transplant Unit, Azienda Ospedaliera di Rilievo Nazionale "San Giuseppe Moscati" (A.O.R.N. Giuseppe Moscati), Avellino, Italy.
¹² Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
¹³ Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.

PMID: 39578528
DOI: 10.1038/s41409-024-02459-0

Abstract

We looked at treatment rates and center density across countries for patients treated in 2022; 46,143 HCTs (19,011 (41.2%) allogeneic, 27,132 (58.8%) autologous) reported by 689 centers. 4329 patients received advanced cellular therapies, 3205 were CAR-T. We found considerable differences in utilization of autologous, allogeneic HCT and more so for CAR-T. Differences in procedure type and for allogeneic HCT in donor use and disease indication are highlighted. For instance, countries with the highest use of unrelated donors per 10 million inhabitants were Germany (297) and the Netherlands (230), for identical sibling HCT it was Israel (148) and Lebanon (113), for haploidentical it was Israel (94) and Italy (94) and for cord blood it was the Netherlands (24) and the United Kingdom (15). We looked at HCT use for specific indications in allogeneic HCT (AML CR1, MDS, MPN and BMF). We correlated treatment rates with GNI and with demographic age structure and show correlations in HCT and CAR-T use and center density, highest in Italy for allogeneic and autologous HCT and in Switzerland for CAR-T. Resource restricted countries tend to concentrate HCT use in a limited number of centers. These data are useful for comparisons across countries.